Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

Lebedinsky, Claudia; Gómez, Javier; Park, Youn C.; Nieto, Antonio; Soto-Matos, Arturo; Parekh, Trilok; Alfaro, Vicente; Roy, E. P.; Lardelli, Pilar; Kahatt, Carmen

doi:10.1007/s00280-011-1614-z

Cited by 26 publications

(19 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of HF remains higher for patients who receive anthracyclines compared with those who receive other agents, even after excluding elderly patients and those with relevant comorbidities . Cancer treatment‐induced HF occurs with several other traditional chemotherapeutic agents, including cyclophosphamide (7%‐28%)and docetaxel (2.3%‐8%) (Table ) . The potential for permanent cardiac damage with exposure to anthracyclines has led to the adoption, in some clinical settings (ie, early stage breast cancer), of chemotherapy regimens with lower cumulative anthracycline exposure.…”

Section: Common CV Adverse Eventsmentioning

confidence: 99%

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Curigliano

Cardinale

Dent

et al. 2016

CA A Cancer J Clinicians

575

427

View full text Add to dashboard Cite

Answer questions and earn CME/CNE Cancer and heart disease are the leading causes of morbidity and mortality in the industrialized world. Modern treatment strategies have led to an improvement in the chances of surviving a diagnosis of cancer; however, these gains can come at a cost. Patients may experience adverse cardiovascular events related to their cancer treatment or as a result of an exacerbation of underlying cardiovascular disease. With longer periods of survival, late effects of cancer treatment may become clinically evident years or decades after completion of therapy. Current cancer therapy incorporates multiple agents whose deleterious cardiac effects may be additive or synergistic. Cardiac dysfunction may result from agents that can result in myocyte destruction, such as with anthracycline use, or from agents that appear to transiently affect left ventricular contractility. In addition, cancer treatment may be associated with other cardiac events, such as severe treatment-induced hypertension and vasospastic and thromboembolic ischemia, as well as rhythm disturbances, including QTc prolongation, that may be rarely life-threatening. Early and late effects of chest radiation can lead to radiation-induced heart disease, including pericardial disease, myocardial fibrosis, cardiomyopathy, coronary artery disease, valvular disease, and arrhythmias, in the setting of myocardial fibrosis. The discipline of cardio-oncology has developed in response to the combined decision making necessary to optimize the care of cancer patients, whether they are receiving active treatment or are long-term survivors. Strategies to prevent or mitigate cardiovascular damage from cancer treatment are needed to provide the best cancer care. This review will focus on the common cardiovascular issues that may arise during or after cancer therapy, the detection and monitoring of cardiovascular injury, and the best management principles to protect against or minimize cardiotoxicity during the spectrum of cancer treatment strategies. CA Cancer J Clin 2016;66:309-325. © 2016 American Cancer Society.

show abstract

Section: Common CV Adverse Eventsmentioning

confidence: 99%

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Curigliano

Cardinale

Dent

et al. 2016

CA A Cancer J Clinicians

575

427

View full text Add to dashboard Cite

show abstract

“…112 Therefore, in 2009, Trabectedin was granted approval for treatment of relapsed platinum-sensitive ovarian cancer in combination with PLD in Europe. 113 …”

Section: Development Of Et-743 (Yondelis®) As a Clinical Drug: Thementioning

confidence: 99%

Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics

et al. 2015

View full text Add to dashboard Cite

The Ecteinascidin family comprises a number of biologically active compounds, containing two to three tetrahydroisoquinoline subunits. Although isolated from marine tunicates, these compounds share a common pentacyclic core with several antimicrobial compounds found in terrestrial bacteria. Among the tetrahydroisoquinoline natural products, Ecteinascidin 743 (Et-743) stands out as the most potent antitumor antibiotics that it is recently approved for treatment of a number of soft tissue sarcomas. In this article, we will review the backgrounds, the mechanism of action, the biosynthesis, and the synthetic studies of Et-743. Also, the development of Et-743 as an antitumor drug is discussed.

show abstract

“…Unlike other commonly used cytotoxic agents, mucositis, diarrhea, alopecia, dermal toxicities, polyneuropathy, nephrotoxicity and cardiotoxicity are uncommon or not reported (Table 4) [40][41][42][43].…”

Section: Miscellaneous Toxicitiesmentioning

confidence: 92%

Trabectedin: Supportive care strategies and safety profile

Jordan¹,

Jahn²,

Jordan³

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

Abstract: Trabectedin has a low incidence of CAEs, consisting mainly of arrhythmias. This extensive data review indicates a low cardiac risk profile for trabectedin.

Cited by 26 publications

References 44 publications

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management

Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics

Trabectedin: Supportive care strategies and safety profile

Contact Info

Product

Resources

About